Which companies are Scinopharm Taiwan's closest peers?

The cockpit's peer set: CHO Pharma (6586.TWO), Monopar Therapeutics (MNPR), Hanx Biopharmaceuticals (Wuhan) (3378.HK), Shanghai ZJ Bio-Tech (688317.SS), Jacobio Pharmaceuticals (1167.HK), Medigen Vaccine Biologics (6547.TWO), Eupraxia Pharmaceuticals (EPRX.TO), Shattuck Labs (STTK).

How has Scinopharm Taiwan stock performed?

Over six months to 6 Nov 2026 the shares returned -1.5% against -11.3% for the median peer; over one year +11.0%.

← CockpitCompetitor Analysis › 1789.TW Scinopharm Taiwan, Ltd.Open in the cockpit ↗

Scinopharm Taiwan, Ltd.1789.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology

Momentum leader 83

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$482M

US dollars, full cap

Free float

32%

of shares outstanding

$/day

$376,820

20-day average traded

Fwd P/E

43.8×

forward earnings

ROIC−WACC

-5.8 pp

WACC 5.0%

Hurdle

+15 pp

Req g minus delivered

Next earnings

117 days

3 Mar 2027

Close · TWDNT$20.15

1D+3.6%

1W+0.8%

1M+8.9%

3M+6.0%

6M-1.5%

YTD+20.3%

1Y+11.0%

ATR %3.0%

52w lowhigh30.8% off high

What Scinopharm Taiwan does

No business profile yet.

Scinopharm Taiwan at a glance

Size Scinopharm Taiwan (1789.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $482M, the 456th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$20.15 on 6 Nov 2026.

Performance Over six months the shares fell 1.5%, against -11.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue fell 4.8% over the last twelve months (peer median -2.2%); the operating margin is -3.6% (peer median -52.6%).

Valuation It trades at 43.8× forward earnings against a peer median of 20.1× (2nd most expensive of 5).

Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.8 points below its cost of capital (5.0% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Scinopharm Taiwan against the median of its 20 peers (local-currency closes).

Scinopharm Taiwan financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	NT$3.04B	NT$3.16B	NT$3.41B	NT$3.19B	NT$3.26B
Revenue growth	—	-7%	+7%	-2%	—
Gross profit	NT$1.14B	NT$988M	NT$1.21B	NT$1.13B	NT$1.15B
EBITDA	n/a	NT$626M	NT$809M	NT$776M	NT$845M
Net income	NT$16.7M	NT$137M	NT$339M	NT$287M	NT$353M
Free cash flow	n/a	NT$306M	NT$471M	-NT$37.2M	NT$530M
Capital expenditure	n/a	NT$298M	NT$300M	NT$285M	NT$250M
Total debt	n/a	NT$763M	NT$677M	NT$621M	NT$678M

Quarterly statements and history in the cockpit →

Scinopharm Taiwan competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Scinopharm Taiwan is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Scinopharm Taiwan is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Scinopharm Taiwan is the large dot.

Scinopharm Taiwan competitors and peer comparison

How Scinopharm Taiwan compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Scinopharm Taiwan against its 20 peers (data as of 6 Nov 2026)
Measure	1789.TW	Peer median	Rank in peer set
1-month return	+8.9%	-13.2%	2nd highest of 21
6-month return	-1.5%	-11.3%	6th highest of 20
Distance from 52-week high	-30.8%	-37.4%	8th highest of 21
Revenue growth (TTM)	-4.8%	-2.2%	6th lowest of 14
Operating margin	-3.6%	-52.6%	6th highest of 15
Forward P/E	43.8×	20.1×	2nd most expensive of 5
Growth the price implies (Req g, 7 yrs)	15.2%	12.1%	3rd least demanding of 5
Growth delivered (Del g)	+0.5%	-19.7%	2nd highest of 5
Hurdle (Req g minus delivered)	+14.7 pp	+28.2 pp	2nd least demanding of 5
ROIC minus cost of capital	-5.8 pp	-16.2 pp	5th highest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g	Delivered g
Scinopharm Taiwan 1789.TW	Taiwan	$482M	-1%	-5%	-4%	43.8×	15.2%	+0.5%
CHO Pharma 6586.TWO	Taiwan	$480M	+57%	-47%	-17,694%	n/a	n/a	n/a
Monopar Therapeutics MNPR	United States	$479M	+12%	n/a	n/a	n/a	n/a	n/a
Hanx Biopharmaceuticals (Wuhan) 3378.HK	Hong Kong	$469M	-13%	n/a	n/a	n/a	n/a	n/a
Shanghai ZJ Bio-Tech 688317.SS	China	$468M	-16%	-18%	-75%	n/a	6.0%	-62.3%
Jacobio Pharmaceuticals 1167.HK	Hong Kong	$468M	-27%	+286%	68%	6.3×	-14.9%	-36.1%
Medigen Vaccine Biologics 6547.TWO	Taiwan	$467M	-5%	+44%	10%	187.6×	n/a	n/a
Eupraxia Pharmaceuticals EPRX.TO	Canada	$466M	-5%	n/a	n/a	n/a	n/a	n/a
Shattuck Labs STTK	United States	$464M	-33%	-67%	-5,571%	n/a	n/a	n/a
Shanghai Obio Technology (Group) 688238.SS	China	$462M	-4%	+20%	-79%	n/a	n/a	n/a
Crescent Biopharma CBIO	United States	$503M	-28%	n/a	-1,418%	n/a	n/a	n/a
Qurient 115180.KS	South Korea	$503M	-59%	-20%	-517%	n/a	n/a	n/a
Berry Genomics 000710.SZ	China	$504M	-5%	-2%	-24%	n/a	n/a	n/a
Komipharm International 041960.KS	South Korea	$460M	-12%	-3%	2%	n/a	n/a	n/a
DiaMedica Therapeutics DMAC	United States	$505M	+48%	n/a	n/a	n/a	n/a	n/a
Neurogene NGNE	United States	$506M	-18%	-100%	n/a	n/a	n/a	n/a
Shanghai Serum Bio-Technology 688163.SS	China	$507M	-11%	-1%	26%	n/a	n/a	n/a
Steminent Biotherapeutics 7729.TWO	Taiwan	$458M	+139%	n/a	n/a	n/a	n/a	n/a
TaiMed Biologics 4147.TWO	Taiwan	$454M	+10%	+4%	-30%	n/a	31.8%	-3.3%
HanchorBio 7827.TW	Taiwan	$511M	n/a	n/a	-225%	2.5×	n/a	n/a
Qingdao Vland Biotech 603739.SS	China	$450M	-21%	+5%	7%	33.9×	18.2%	+7.3%

Questions

Which companies are Scinopharm Taiwan's closest peers?: The cockpit's peer set: CHO Pharma (6586.TWO), Monopar Therapeutics (MNPR), Hanx Biopharmaceuticals (Wuhan) (3378.HK), Shanghai ZJ Bio-Tech (688317.SS), Jacobio Pharmaceuticals (1167.HK), Medigen Vaccine Biologics (6547.TWO), Eupraxia Pharmaceuticals (EPRX.TO), Shattuck Labs (STTK).
Is Scinopharm Taiwan expensive compared with its peers?: On forward p/e it trades at 43.8× against a peer median of 20.1×, 2nd most expensive of 5 in its peer set. For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Scinopharm Taiwan stock performed?: Over six months to 6 Nov 2026 the shares returned -1.5% against -11.3% for the median peer; over one year +11.0%.